Cover Image
市場調查報告書

日本的介入冠狀動脈導管設備市場分析

Japan Market Report for Interventional Coronary Catheters 2018 - MedCore

出版商 iData Research Inc. 商品編碼 616041
出版日期 內容資訊 英文 682 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本的介入冠狀動脈導管設備市場分析 Japan Market Report for Interventional Coronary Catheters 2018 - MedCore
出版日期: 2017年10月01日 內容資訊: 英文 682 Pages
簡介

本報告提供日本國內的介入冠狀動脈導管的市場相關分析,提供疾病概要,及市場基本結構·最新形勢,市場規模·收益額·成長率·平均價格的轉變及預測 (過去4年·今後7年份),各類別產品詳細趨勢,主要的推動及阻礙市場要素,市場佔有率結構等調查,並彙整近幾年的企業間競爭·資本交易情勢等資訊,為您概述為以下內容。

摘要整理

日本的心血管介入設備市場概要

競爭分析

市場趨勢

市場發展

分析對象市場

分析對象的治療

過去的版本

分析方法

  • IDATA的9級分析方法

疾病概要

  • 人體的基本結構
  • 疾病的治療·診斷方法
    • 一般的診斷方法
    • 冠狀動脈疾病 (CAD)
    • 心肌梗塞 (MI)
    • 心絞痛
  • 患者的人口組成
    • 全般的統計資料

產品評估

  • 產品系列
    • 冠狀動脈導管
      • 診斷用冠狀動脈導管
      • 介入冠狀動脈導管
      • IVUS (血管內超音波檢驗) 支援導管
      • OCT (光學同調斷層法) 支援導管
  • 法規方面的課題和回收
    • Boston Scientific
    • Cardinal Health
    • Cook Medical
    • Cordis (Cardinal Health)
    • Medtronic
    • Merit Medical Systems
    • Spectranetics
    • St. Jude Medical (Abbott Laboratories)
    • Vascular Solutions (Teleflex)
    • Volcano Therapeutics (Philips Volcano)
    • 其他的企業
  • 臨床實驗趨勢
    • Abbott Laboratories
    • ASAHI INTECC CO., LTD.
    • B. Braun
    • Biosensors
    • Biotronik
    • Boston Scientific
    • Medtronic
    • St. Jude Medical (Abbott Laboratories)
    • Terumo Interventional Systems (TIS)
    • 其他的企業

介入冠狀動脈導管市場

  • 簡介
  • 市場分析與預測
  • 推動及阻礙市場要素
    • 推動市場要素
    • 阻礙市場要素
  • 各企業市場佔有率分析

簡稱一覽

附錄I:企業的新聞稿

目錄
Product Code: iDATA_JPIC18_MC_ICC

Interventional catheters are used by physicians in procedures for the placement of devices such as stents and balloons. There is a large variety of catheters, and their use depends on the size, shape and curvature of the lesion. Cardiologists tend to choose catheters based on their guidewire selection. Interventional catheters must be rigid without being stiff, because the device must adapt itself to the curvature of certain arteries. In addition, catheters must promptly react to a physician's movements, sometimes following zigzag patterns, without risking puncturing the lumen.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

Guiding catheters run over guidewires and are used at the beginning of an interventional procedure. However, if a guiding catheter cannot cross an occluded lesion, a more specialized device, such as a support catheter may be employed. Support catheters are able to cross all but the most occluded lesions, although their success depends on the skill and perseverance of the physician. Some lesions are too occluded even for support catheters, and a physician will use a chronic total occlusion (CTO) or atherectomy device in those situations. Usually, lesions that are so occluded can be spotted via X-ray imaging prior to the start of an interventional procedure.

Guiding catheters are used for conventional lesions where minimal support is required, whereas support catheters are used for occluded lesions where more rigidity and torque may be required to cross the lesion. Support catheters are predominantly used for peripheral procedures, and are seldom used for coronary procedures. Within the coronary area, CTO devices are usually used for more occluded lesions, lessening the demand for support catheters within this area.

For these reasons, only guiding catheters are included in this analysis.

Table of Contents

TABLE OF CONTENTS I

LIST OF FIGURES XXII

LIST OF CHARTS XXX

EXECUTIVE SUMMARY 1

JAPAN INTERVENTIONAL CARDIOLOGY MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 9

MARKETS INCLUDED 10

PROCEDURES INCLUDED 11

VERSION HISTORY 11

RESEARCH METHODOLOGY 12

    • Step 1: Project Initiation & Team Selection 12
    • Step 2: Prepare Data Systems and Perform Secondary Research 15
    • Step 3: Preparation for Interviews & Questionnaire Design 17
    • Step 4: Performing Primary Research 18
    • Step 5: Research Analysis: Establishing Baseline Estimates 20
    • Step 6: Market Forecasts and Analysis 21
    • Step 7: Identify Strategic Opportunities 23
    • Step 8: Final Review and Market Release 24
    • Step 9: Customer Feedback and Market Monitoring 25

DISEASE OVERVIEW 26

  • 2.1 BASIC ANATOMY 26
  • 2.2 DISEASE TREATMENTS AND DIAGNOSTICS 28
    • 2.2.1 General Diagnostics 28
    • 2.2.2 Coronary Artery Disease (CAD) 28
    • 2.2.3 Myocardial Infarction (MI) 29
    • 2.2.4 Angina Pectoris 30
  • 2.3 PATIENT DEMOGRAPHICS 31
    • 2.3.1 General Statistics 31

PRODUCT ASSESSMENT 33

  • 3.1 PRODUCT PORTFOLIOS 33
    • 3.1.1 Coronary Catheters Market 33
      • 3.1.1.1 Diagnostic Coronary Catheter 33
      • 3.1.1.2 Interventional Coronary Catheters 34
      • 3.1.1.3 Intravascular Ultrasound (IVUS) Catheter 34
      • 3.1.1.4 Optical Coherence Tomography (OCT) Catheter 35
  • 3.2 REGULATORY ISSUES AND RECALLS 41
    • 3.2.1 Boston Scientific 41
      • 3.2.1.1 Coronary Stent 41
      • 3.2.1.2 PTCA Balloon Catheter 41
      • 3.2.1.3 Interventional Coronary Catheters and Guidewires 42
      • 3.2.1.4 Coronary Embolic Protection Device 43
    • 3.2.2 Cardinal Health 43
      • 3.2.2.1 Coronary Vascular Closure Device 43
    • 3.2.3 Cook Medical 44
      • 3.2.3.1 Coronary Stent 44
      • 3.2.3.2 Interventional Coronary Catheters and Guidewires 44
    • 3.2.4 Cordis (Cardinal Health) 45
      • 3.2.4.1 PTCA Balloon Catheter/Dilation Catheters 45
      • 3.2.4.2 Interventional Coronary Catheters and Guidewires 46
    • 3.2.5 Medtronic 47
      • 3.2.5.1 Coronary Stent 47
      • 3.2.5.2 PTCA Balloon and Dilation Catheters 47
      • 3.2.5.3 Interventional Coronary Catheters and Guidewires 48
    • 3.2.6 Merit Medical Systems 51
      • 3.2.6.1 Interventional Coronary Catheters and Guidewires 51
      • 3.2.6.2 Coronary Introducer Sheath 53
    • 3.2.7 Spectranetics 54
      • 3.2.7.1 Coronary Atherectomy Device 54
    • 3.2.8 St. Jude Medical (Abbott Laboratories) 55
      • 3.2.8.1 Coronary Vascular Closure Device 55
      • 3.2.8.2 Interventional Coronary Catheters and Guidewires 55
    • 3.2.9 Vascular Solutions (Teleflex) 56
      • 3.2.9.1 Interventional Coronary Catheters and Guidewires 56
    • 3.2.10 Volcano Therapeutics (Philips Volcano) 57
      • 3.2.10.1 Interventional Coronary Catheters and Guidewires 57
      • 3.2.10.2 Intravascular Ultrasound (IVUS) Catheter 57
    • 3.2.11 Other Companies 58
      • 3.2.11.1 Coronary Stent and other Vascular Stents 58
      • 3.2.11.2 PTCA balloon catheter 58
      • 3.2.11.3 Interventional Coronary Catheters and Guidewires 59
      • 3.2.11.4 Coronary Atherectomy Device 61
      • 3.2.11.5 Coronary Introducer Sheath 62
      • 3.2.11.6 Intravascular Ultrasound (IVUS) Catheter 62
  • 3.3 CLINICAL TRIALS 63
    • 3.3.1 Abbott Laboratories 63
      • 3.3.1.1 Coronary Stent 63
    • 3.3.2 Asahi Intecc 72
      • 3.3.2.1 Interventional Coronary Catheters and Guidewires 72
    • 3.3.3 B. Braun 73
      • 3.3.3.1 Coronary Stent 73
      • 3.3.3.2 PTCA balloon catheter 74
    • 3.3.4 Biosensors 78
      • 3.3.4.1 Coronary Stent 78
    • 3.3.5 Biotronik 80
      • 3.3.5.1 Coronary Stent 80
      • 3.3.5.2 PTCA balloon catheter 83
    • 3.3.6 Boston Scientific 84
      • 3.3.6.1 Coronary Stent 84
      • 3.3.6.3 PTCA balloon catheter 87
      • 3.3.6.4 Coronary Embolic Protection Device 87
    • 3.3.7 Medtronic 88
      • 3.3.7.1 Coronary Stent 88
      • 3.3.7.2 Interventional Coronary Catheters and Guidewires 91
      • 3.3.7.3 Coronary Embolic Protection Device 92
    • 3.3.8 St. Jude Medical (Abbott Laboratories) 93
      • 3.3.8.1 Interventional Coronary Catheters and Guidewires 93
      • 3.3.8.2 Intravascular Ultrasound (IVUS) Catheter 93
      • 3.3.8.3 Optical Coherence Tomography Catheter 94
      • 3.3.8.4 Fractional Flow Reverse (FFR) Catheter 94
    • 3.3.9 Terumo Interventional Systems (TIS) 95
      • 3.3.9.1 Interventional Coronary Catheters and Guidewires 95
      • 3.3.9.2 Coronary Embolic Protection Device 95
    • 3.3.10 Other Companies 96
      • 3.3.10.1 Coronary Stent 96
      • 3.3.10.2 PTCA balloon catheter 108
      • 3.3.10.3 Interventional Coronary Catheters and Guidewires 109
      • 3.3.10.4 Coronary Embolic Protection Device 112
      • 3.3.10.5 Coronary Chronic Total Occlusion Crosser CTO 113
      • 3.3.10.7 Fractional Flow Reserve (FFR) Guidewire 114
      • 3.3.10.8 Optical Coherence Tomography (OCT) Guidewire 114

INTERVENTIONAL CORONARY CATHETER MARKET 116

  • 4.1 INTRODUCTION 116
  • 4.2 MARKET ANALYSIS AND FORECAST 117
  • 4.3 DRIVERS AND LIMITERS 119
    • 4.3.1 Market Drivers 119
    • 4.3.2 Market Limiters 119
  • 4.4 COMPETITIVE MARKET SHARE ANALYSIS 121

ABBREVIATIONS 125

APPENDIX: COMPANY PRESS RELEASES 127

LIST OF CHARTS

  • Chart 1 1: Interventional Cardiology Market by Segment, Japan, 2014 - 2024 3
  • Chart 1 2: Interventional Cardiology Market Overview, Japan, 2017 & 2024 3
  • Chart 9 1: Interventional Coronary Catheter Market, Japan, 2014 - 2024 118
  • Chart 9 2: Leading Competitors, Interventional Coronary Catheter Market, Japan, 2017 124

LIST OF FIGURES

  • Figure 1 1: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (1 of 2) 4
  • Figure 1 2: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (2 of 2) 5
  • Figure 1 3: Companies Researched in this Report, Japan, 2017 6
  • Figure 1 4: Factors Impacting the Interventional Cardiology Market by Segment, Japan (1 of 2) 7
  • Figure 1 5: Factors Impacting the Interventional Cardiology Market by Segment, Japan (2 of 2) 8
  • Figure 1 6: Recent Events in the Interventional Cardiology Market, Japan, 2014 - 2017 9
  • Figure 1 7: Interventional Cardiology Markets Covered, Japan, 2017 10
  • Figure 1 8: Interventional Cardiology Procedures Covered, Japan, 2017 11
  • Figure 1 9: Version History 11
  • Figure 3 7: Coronary Catheters Products by Company (1 of 3) 37
  • Figure 3 8: Coronary Catheters Products by Company (2 of 3) 38
  • Figure 3 9: Coronary Catheters Products by Company (3 of 3) 39
  • Figure 3 10: Imaging Catheter Products by Company 40
  • Figure 3 20: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 41
  • Figure 3 21: Class 2 Device Recall Boston Scientific, Small Peripheral Cutting BalloonTM 41
  • Figure 3 22: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 41
  • Figure 3 23: Class 2 Device Recall Boston Scientific ACUITY Pro Coronary Sinus Guide Catheter 42
  • Figure 3 24: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 42
  • Figure 3 25: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 42
  • Figure 3 26: Class 1 Device Recall RotaWire Elite and sireClip Torquer, Guidewire and Guidewire Manipulation Device, Floppy 43
  • Figure 3 27: Class 2 Device Recall MynxGrip Vascular Closure Device 43
  • Figure 3 28: Class 2 Device Recall Zilver 518RX Vascular Stent 44
  • Figure 3 29: Class 2 Device Recall Zilver 518 Vascular Self Expanding Stent 44
  • Figure 3 30: Class 2 Device Recall White Lumax Guiding Coaxial Catheter 44
  • Figure 3 31: Class 2 Device Recall Cordis POWERFLEX PRO PTA Dilatation Catheter 45
  • Figure 3 32: Class 2 Device Recall EMPIRA ? NC RX PTCA Dilatation Catheter 45
  • Figure 3 33: Class 2 Device Recall Cordis EMPIRA RX PTCA Dilatation Catheter 45
  • Figure 3 34: Class 2 Device Recall Cordis ADROIT 6F Guiding Catheter 46
  • Figure 3 35: Class 2 Device Recall Resolute Integrity Zotarolimuseluting Coronary Stent 47
  • Figure 3 36: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter 47
  • Figure 3 37: Class 2 Device Recall Ev3, Inc. (Medtronic) 47
  • Figure 3 38: Class 2 Device Recall NC Sprinter; Rapid Exchange Balloon Dilatation Catheter 48
  • Figure 3 39: Class 2 Device Recall Medtronic Launcher Coronary Guide Catheter 48
  • Figure 3 40: Class 2 Device Recall Launcher Coronary Guiding Catheter 48
  • Figure 3 41: Class 1 Device Recall ZINGER Steerable Guidewire 48
  • Figure 3 42: Class 1 Device Recall Cougar Nitinol Workhorse Guidewire 49
  • Figure 3 43: Class 1 Device Recall COUGAR Steerable Guidewire 49
  • Figure 3 44: Class 1 Device Recall THUNDER Steerable Guidewire 49
  • Figure 3 45: Class 1 Device Recall ProVia CROSSING GUIDEWIRE 49
  • Figure 3 46: Class 1 Device Recall ATTAIN HYBRID Guide Wire 50
  • Figure 3 47: Class 2 Device Recall Medtronic Zuma Guide Catheter 50
  • Figure 3 48: Class 2 Device Recall Merit Maestro Microcatheter 51
  • Figure 3 49: Class 2 Device Recall Merit Laureate Hydrophilic Guide Wire 51
  • Figure 3 50: Class 2 Device Recall Maestro Microcatheter, Merit Medical System 51
  • Figure 3 51: Class 2 Device Recall Performa Cardiac Multipack Catheter 52
  • Figure 3 52: Class 2 Device Recall Hydrophylic guidewire 52
  • Figure 3 53: Class 2 Device Recall PreludeEASE 53
  • Figure 3 54: Class 2 Device Recall Prelude Pro Sheath Introducter 53
  • Figure 3 55: Class 2 Device Recall Turbo Elite Atherectomy Catheter 54
  • Figure 3 56: Class 2 Device Recall ELCA Coronary Atherectomy Catheter 54
  • Figure 3 57: Class 2 Device Recall Vascular closure device 55
  • Figure 3 58: Class 3 Device Recall FastCath" Transseptal Guiding Introducer 55
  • Figure 3 59: Class 1 Device Recall TwinPass Dual Access Catheter 56
  • Figure 3 60: Class 2 Device Recall Percutaneous Catheter 56
  • Figure 3 61: Class 2 Device Recall Prestige Plus Wire 57
  • Figure 3 62: Class 2 Device Recall Volcano s5, s5i, CORE and CORE Mobile systems 57
  • Figure 3 63: Class 2 Device Recall Intravascular Ultrasound System 57
  • Figure 3 64: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular 58
  • Figure 3 65: Class 1 Device Recall LifeStent Solo Vascular Stent, Bard Peripheral Vascular 58
  • Figure 3 66: Class 2 Device Recall PTA Balloon Dilatation Catheters 58
  • Figure 3 67: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc. 59
  • Figure 3 68: Class 2 Device Recall Coronary Artery Perfusion Cannula with Balloon, Sorin Group USA, Inc. 59
  • Figure 3 69: Class 2 Device Recall Aortic Arch Cannula, Sorin Group USA, Inc. 59
  • Figure 3 70: Class 2 Device Recall Mallinckrodt Launcher Guiding Catheter, Stryker Sustainability Solutions 59
  • Figure 3 71: Class 2 Device Recall Distal Access Catheter (DAC), Concentric Medical Inc 60
  • Figure 3 72: Class 2 Device Recall Distal Access Catheter 60
  • Figure 3 73: Class 2 Device Recall Proplege Coronary Sinus Catheter, Edwards Lifesciences, LLC 60
  • Figure 3 74: Class 2 Device Recall Turbo Elite, ELCA Atherectomy Catheter, Spectranetics Corporation 61
  • Figure 3 75: Class 1 Device Recall Diamondback 360 Coronary Orbital Artherctomy System, Cardiovascular Systems, Inc. 61
  • Figure 3 76: Class 3 Device Recall Diamondback 360 Coronary Orbital Atherectomy System 61
  • Figure 3 77: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc 62
  • Figure 3 78: Class 1 Device Recall Halo One ThinWalled Guiding Sheath, Bard Peripheral Vascular 62
  • Figure 3 79: Class 2 Device Recall SOUNDSTAR eco Catheter, Biosense Webster, Inc. 62
  • Figure 3 80: XIENCE Xpedition/Alpine in Routine Clinical Practice (IRIS XPEDITION) 63
  • Figure 3 81: Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC) 63
  • Figure 3 82: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 64
  • Figure 3 83: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE) 64
  • Figure 3 84: XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS) 65
  • Figure 3 85: Absorb IV Randomized Controlled Trial 65
  • Figure 3 86: Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA) 66
  • Figure 3 87: Xience Versus Synergy in Left Main PCI (IDEAL-LM) 66
  • Figure 3 88: Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) 67
  • Figure 3 89: XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS) 67
  • Figure 3 90: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS) 68
  • Figure 3 91: A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA) 68
  • Figure 3 92: AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN) 69
  • Figure 3 93: XIENCE PRIME Japan Post-Marketing Surveillance (PMS) 69
  • Figure 3 94: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent, Performance, and Technique in Chronic Total Occlusions 70
  • Figure 3 95: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE (PATRIOT) 70
  • Figure 3 96: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V) 71
  • Figure 3 97: Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE) 71
  • Figure 3 98: The Asahi Intecc PTCA Chronic Total Occlusion Study (CTO-PCI) 72
  • Figure 3 99: Optilene® Suture for Coronary Artery Bypass Graft Surgery (OPTICABG) 73
  • Figure 3 100: Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent 73
  • Figure 3 101: Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV) 74
  • Figure 3 102: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) 74
  • Figure 3 103: Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions (PEPCAD V) 75
  • Figure 3 104: The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations (PEPCAD-BIF) 75
  • Figure 3 105: INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent (INDICOR) 76
  • Figure 3 106: A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD) 76
  • Figure 3 107: The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO) 77
  • Figure 3 108: PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel 77
  • Figure 3 109: LEADERS FREE II: BioFreedom™ Pivotal Study 78
  • Figure 3 110: BioFreedom US IDE Feasibility Trial 78
  • Figure 3 111: A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free) 79
  • Figure 3 112: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease (ABSORB-LONG) 80
  • Figure 3 113: BIOTRONIK Orsiro Pre-Marketing Registration (BIOFLOW-VI) 80
  • Figure 3 114: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions 81
  • Figure 3 115: BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite 81
  • Figure 3 116: BIOHELIX-I Bare Metal Stent Study (BIOHELIX-I) 82
  • Figure 3 117: BIOFLOW III Asia Registry 82
  • Figure 3 118: BIOFLOW-III Israel Satellite Registry 82
  • Figure 3 119: Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT (REMEDEE-OCT) 83
  • Figure 3 120: Drug Eluting Pantera Lux Catheter Registry 83
  • Figure 3 121: Post-Approval Study of PROMUS Element™ in China (PEChina) 84
  • Figure 3 122: EVOLVE China Clinical Trial (EVOLVE China) 84
  • Figure 3 123: EVOLVE Short DAPT Study 85
  • Figure 3 124: PROMUS Element Plus US Post-Approval Study 85
  • Figure 3 125: The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) 86
  • Figure 3 126: SYNERGY China: Assess SYNERGY Stent in China 86
  • Figure 3 127: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter 87
  • Figure 3 128: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation 87
  • Figure 3 129: Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions 88
  • Figure 3 130: RESOLUTE ONYX Post-Approval Study (ONYX PAS) 88
  • Figure 3 131: Medtronic RevElution Trial (RevElution) 89
  • Figure 3 132: The European Bifurcation Club Left Main Study (EBC MAIN) 89
  • Figure 3 133: Medtronic Resolute Onyx 2.0 mm Clinical Study 89
  • Figure 3 134: Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study 90
  • Figure 3 135: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY) 90
  • Figure 3 136: An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (RI-US) 91
  • Figure 3 137: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 91
  • Figure 3 138: Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP) 92
  • Figure 3 139: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) 93
  • Figure 3 140: ILUMIEN III: OPTIMIZE PCI 93
  • Figure 3 141: ILUMIEN III: OPTIMIZE PCI 94
  • Figure 3 142: Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease (POST-IT) 94
  • Figure 3 143: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 95
  • Figure 3 144: Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis 95
  • Figure 3 145: Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s) 96
  • Figure 3 146: Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) 96
  • Figure 3 147: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 97
  • Figure 3 148: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR) 97
  • Figure 3 149: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 98
  • Figure 3 150: BIONICS - Pharmacokinetics (PK) Trial (BIONICS) 98
  • Figure 3 151: Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT II) 98
  • Figure 3 152: Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 ) 99
  • Figure 3 153: Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease (Firehawk_38) 99
  • Figure 3 154: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II) 100
  • Figure 3 155: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT) 100
  • Figure 3 156: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II), Reva Medical 100
  • Figure 3 157: Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I) (FANTOM I), Reva Medical 101
  • Figure 3 158: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial 101
  • Figure 3 159: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus) 102
  • Figure 3 160: Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II) 102
  • Figure 3 161: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis 103
  • Figure 3 162: eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries (eTRYTONLM) 103
  • Figure 3 163: An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial (MeriT-II) 104
  • Figure 3 164: An BioMime Vs. Xience Randomised Control Clinical Study (meriT-V) 104
  • Figure 3 165: BIONICS Israel Trial 105
  • Figure 3 166: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System 105
  • Figure 3 167: Sapphire II PRO US Clinical Study 106
  • Figure 3 168: Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM) 106
  • Figure 3 169: Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I) 106
  • Figure 3 170: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 107
  • Figure 3 171: Procedural Advantages of a Novel Drug-Eluting Coronary Stent 107
  • Figure 3 172: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study 108
  • Figure 3 173: Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) 108
  • Figure 3 174: Drug Eluting Balloon for Prevention of Constrictive Remodeling 109
  • Figure 3 175: Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis 109
  • Figure 3 176: Real-time MRI Right Heart Catheterization Using Passive Catheters 110
  • Figure 3 177: A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions 110
  • Figure 3 178: Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI (RAPID) 111
  • Figure 3 179: A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter 111
  • Figure 3 180: Performance of the CARDIOGARD Cannula (GECG) 112
  • Figure 3 181: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR 112
  • Figure 3 182: Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft 113
  • Figure 3 183: Coherex WAVECREST I Left Atrial Appendage Occlusion Study 113
  • Figure 3 184: Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter 114
  • Figure 3 185: Prospective Randomized Optical Coherence Tomography Oslo tRial (PROCTOR) 114
  • Figure 3 186: Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation (OCTACS) 115
  • Figure 9 1: Interventional Coronary Catheter Market, Japan, 2014 - 2024 117
  • Figure 9 2: Drivers and Limiters, Interventional Coronary Catheter Market, Japan, 2017 120
  • Figure 9 3: Leading Competitors, Interventional Coronary Catheter Market, Japan, 2017 123
  • Figure 21 1: Press Release Summary 127
Back to Top